Combinatory Effect of ALA-PDT and Itraconazole Treatment for Trichosporon asahii

Yu Lan1,2, Sha Lu1, Bowen Zheng1,3

  • 1Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 West Yanjiang Road, Guangzhou, 510120, China.

Abstract

Insights

This study shows that 5-aminolevulinic acid photodynamic therapy (ALA-PDT) combined with itraconazole effectively treats Trichosporon asahii infections by disrupting biofilms. This combination therapy enhances antifungal efficacy against drug-resistant strains.

Area of Science:

  • Medical Mycology
  • Photomedicine
  • Antimicrobial Resistance

Background:

  • Trichosporon asahii causes opportunistic infections, often resistant to antifungals.
  • Biofilms exacerbate virulence and treatment challenges in trichosporonosis.
  • Photodynamic therapy (PDT) offers a novel approach for fungal infections.

Purpose of the Study:

  • To explore the efficacy of 5-aminolevulinic acid PDT (ALA-PDT) combined with an antifungal agent against Trichosporon asahii.
  • To investigate the synergistic potential of ALA-PDT and itraconazole in treating T. asahii infections, including biofilms.
  • To evaluate ALA-PDT's antimicrobial mechanism against T. asahii.

Main Methods:

  • In vitro biofilm formation using a 96-well plate method.
  • Exposure of planktonic and biofilm T. asahii to varying ALA concentrations and light doses.
  • Antifungal efficacy assessed by colony-forming unit counts and XTT reduction assays.
  • Minimal inhibitory concentration determination and scanning electron microscopy (SEM) for biofilm disruption.

Main Results:

  • Successful clinical treatment of a T. asahii skin infection using combination therapy.
  • ALA-PDT demonstrated dose-dependent antifungal effects on planktonic and adherent T. asahii.
  • ALA-PDT increased susceptibility to itraconazole and showed synergistic effects with itraconazole against biofilms.
  • SEM confirmed significant biofilm disruption by ALA-PDT, enhanced by itraconazole.

Conclusions:

  • ALA-PDT presents a promising alternative strategy for managing Trichosporon infections.
  • Combination therapy of ALA-PDT and itraconazole significantly enhances the elimination of planktonic cells and biofilms.
  • This approach holds potential for treating challenging trichosporonosis cases, including those with drug resistance.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
95
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.1K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
470
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
342
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
310